tbuckley/cabot-search huggingface dataset:
Cigarette smoking as a risk factor in stroke
Authors: J. R. Varma
Journal: JAMA (1988)

<h3>To the Editor.—</h3> I wish to refer to the article in the Feb 19 issue of<i>JAMA</i>by Wolf et al<sup>1</sup>concerning the relationship between cigarette smoking and the incidence of stroke. It is not surprising that the study found a significant relationship to stroke after age and hypertension were taken into account. It is further enlightening that smoking continued to be a significant independent factor in stroke and brain infarction after other risk factors were added. The hazards of smoking, the morbidity associated with this vice or habit, and the high mortality related to diseases associated with smoking are a curse to humanity. The amount of personal misery, man-hours lost in productivity, deprivation in family life, economic impact, burden on health care resources, and other hidden factors is far in excess of the revenues generated from tobacco-related industries. Is it not time for physicians to band together—the American
Abdominal obesity is associated with increased risk of acute coronary events in men
Authors: Hanna-Maaria Lakka, Jukka T Salonen, Timo A Lakka
Journal: Circulation (2001)

P68 Obesity is an important risk factor for coronary heart disease (CHD), but the relative importance of overall and abdominal obesity is unclear. Abdominal obesity has been linked to several atherogenic disorders through which it could increase coronary risk. We investigated the associations of overall and abdominal obesity with the risk of acute coronary events and possible biological mechanisms underlying the relationships in a prospective population-based study among 1346 men aged 42-60 years in Finland. Body mass index (BMI) was used as a measure of overall obesity and waist-to-hip ratio (WHR) and waist circumference (WC) were used as measures of abdominal obesity. Data on acute coronary events were obtained by computer linkage to national hospital discharge and death certificate registers. There were 111 acute coronary events during an average follow up of 10 years. Men with the WHR of 0.91-0.94, 0.95-0.98 and &gt;0.98 (three highest quartiles) had a 3.34-fold (95% CI 1.57-7.10, p=0.002), 2.97-fold (1.39-6.34, 0.005) and 3.40-fold (1.61-7.18, 0.001) risk of acute coronary events, respectively, compared with men with the WHR of &lt;0.91 (lowest quartile) adjusting for confounders. Men with the WC of 83.5-89.5 cm, 90.0-95.5 cm and &gt;95.5 cm (three highest quartiles) had a 1.29-fold (0.71-2.37), 1.70-fold (0.96-3.02) and 1.94-fold (1.10-3.40, 0.021) risk of acute coronary events compared with men with the WC of &lt;83.5 cm (lowest quartile). These associations were partly explained by serum HDL cholesterol, triglycerides and apolipoprotein B, systolic and diastolic blood pressure, diabetes, fasting serum insulin, plasma fibrinogen and serum uric acid. BMI had a markedly weaker association with coronary risk than WHR or WC. Men with both overall and abdominal obesity (BMI ≥25.0 kg/m 2 and WHR ≥0.91) had a 4.56-fold risk of acute coronary events compared with men without obesity. This study indicates that even mild abdominal obesity is independently associated with increased risk of CHD, and that the association is partly explained by other coronary risk factors. This study also suggests that abdominal obesity has a stronger association with coronary risk than overall obesity.
The Pathology and Treatment of Suppurative Diseases of the Ear: Being an abstract of the Harveian Lectures delivered before the Harveian Society of London
Authors: G. P. Field
Journal: BMJ (1892)

rTwoXBDg 1229 able skill, and enjoys the reputation of being able to drive a shrewd bargain.An almost continuous tinnitus aurium troubles him, but it is not sufficiently intense to cause any very great annoyance.At the present time he does not suffer from headache.The 2V~4 V Fig. 3.-Side view of Wae and neck, showing geLeral enlaxgement of features and cervi¢o-dorsal kyphosis.first Eiound of the heart is weak, and he has had two "or three ,epileptiform syncopal attacks, but there is no irregularity -of the pulse and no dropsy of the limbs.IdEASUREMBNTS OF THE PATIENT.8Inches.lLength of hand from lower fold of wrist to end of middle finger ... 83 Length of middle fin 4er from palmar fold at its base ... ... 3t
History
Authors: Laura D. Hirshbein
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Organic Medicinal Chemicals (Synthetic and Natural).
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Apoptosis induction in isolated mouse hepatocytes by immunosuppressants in vitro Department of surgery II and *Equipment Center for Research and Education, Nagoya University, School of Medicine
Journal: Hepatology (1995)

To clarify the role of basophils in the pathogenesis of allergic disease, we developed a new method for performing surface phenotyping of these cells in centrifugation-enriched mononuclear cell fraction. This method identified basophils on the basic of a negative reactivity with mixed FITC-conjugated monoclonal anti-bodies (mAbs) (anti-CD2, -CD14, -CD16, and -CD19) with analysis performed by flow cytometry. The validity of this approach was confirmed by sorting experiments. Various PE-conjugated mAbs were also used to examine binding to FITC-negative basophils. Basophils from asthmatic patients (n = 14) as well as from normal subjects (n = 6) were shown to express CDw32 (FcγRII), CD25 (IL-2R), but not CD64 (FcγRI). We also detected binding of IgG1 and IgG4 to basophils. This method of phenotyping was very rapid and simple. It thus appears to be useful in the study of allergic disease, as well as of the biology of the basophil.
<i>State of New York. State Commission in Lunacy.</i>Twentieth Annual Report. October 1, 1907, to September 30, 1908. Albert Warren Ferris, Sheldon T. Viele, William L. Parkhurst, Commissioners; T. E. McGarr, Secretary. (Albany: J. B. Lyon Company, State Printers, 1909.)
Journal: American Journal of Psychiatry (1910)
Hodgkin's Disease — Prognosis, Treatment and Etiologic and Immunologic Considerations
Authors: Alan C. Aisenberg
Journal: New England Journal of Medicine (1964)

Etiologic ConsiderationsIt could be argued that an extended discussion of the etiology of Hodgkin's disease, whose cause is unknown, is hardly warranted. Yet a considerable body of information has been accumulated over the past twenty years that bears directly or indirectly on the causation of Hodgkin's disease. Although it is customary to classify this condition with neoplastic diseases, there are two serious objections that make it hard to accept the majority of cases of Hodgkin's granuloma as examples of conventional neoplasm. The first is that the clinical picture of Hodgkin's disease, frequently characterized by chills, sweats, fever, leukocytosis, anemia . . .
Diagnostic Electrocardiography and Vector-cardiography
Authors: David H. Spodick
Journal: JAMA (1978)

Each year's crop of ECG texts includes so many good ones that it is difficult to discern a truly outstanding book. This one fills the bill. A worthy successor to the original (<i>JAMA</i>216:2019, 1971), this edition has many new illustrations and encompasses every noteworthy advance. In doing this, Dr Friedman has avoided traditional oversimplifications and the "cookbook" approach of many successful texts, while preserving his customary clarity in dealing with even the most technical points. The chapter on electrophysiology, for example, covers the state of the art along with simple, clear diagrams, which both the novice and the connoisseur will appreciate. A comprehensive discussion of P-wave abnormalities is appropriately cautious in dealing with atrial enlargement and hypertrophy. Each chapter presents the facts in logical order and concludes with a "Concepts" section that analyzes their theoretical and practical aspects. Thus, there are caveats about the tangential validity of many useful
In Reply:
Authors: Michael Auerbach, Harold Ballard, Marilyn McIlwain
Journal: Journal of Clinical Oncology (2004)

Auerbach et al 1 report on a randomized trial of iron supplement in cancer patients with chemotherapy-related anemia receiving recombinant human erythropoietin (rHuEPO).This study is important, because in previous clinical trials of rHuEPO, iron usage has never been energetically pursued in cancer patients and its use has been generally left to the discretion of the individual investigator.We would like to make the following remarks about the Auerbach et al trial for better interpretation of results.(1) Criteria for defining absolute or functional iron deficiency adopted by the authors should be detailed, as there is not concordance in the literature about this point 2 ; (2) the fraction of patients with absolute iron deficiency within the four study groups should be specified.Because of absence of iron stores, in this subset of patients, it is clinically cautious to postpone treatment with erythropoietic agents until iron stores are replenished or to treat iron deficiency aggressively along with rHuEPO therapy.In the same circumstances, administration of rHuEPO alone would be pathophysiologic nonsense. 3hen functional iron deficiency is present in patients receiving rHuEPO, iron repletion is already recommended based on indirect evidence and biologic inferences as literally stated in the American Society of Clinical Oncology/American Society of Hematology guidelines. 4The study by Auerbach et al 1 addresses this issue in a controlled trial for the first time and confirms that iron supplement should be given intravenously rather then orally, as the latter is shown largely ineffective in cancer patients as it also occurs in the setting of anemia in other chronic diseases. 5 major point that remains to be elucidated in the field of rHuEPO therapy for anemia of cancer is whether iron supplement is capable of increasing the fraction of patients without iron deficiency responding to erythropoietic agents.Owing to the increased erythropoietic activity stimulated by rHuEPO, adequate delivery of iron to the bone marrow from the beginning of rHuEPO therapy may well optimize response in these patients as well (ie, by avoiding the development of iron deficiency, whose occurrence during rHuEPO therapy represents a major limitation to its efficacy). 2This important point should be addressed in future prospective trials.
Prevention of infection during peritoneal dialysis
Authors: F. D. Schwartz
Journal: JAMA (1967)

During the past three years, the procedure for peritoneal dialysis was altered in an effort to reduce the incidence of infection. Three consecutive groups of patients were treated by three different regimens. Initially, in 1964, a large-bore indwelling peritoneal catheter was inserted surgically, and the duration of dialysis was prolonged for periods up to 29 days. Prophylactic antibiotics were not administered but protective isolation of the patient was employed. During that year, peritonitis occurred in almost 50% of patients and was caused solely by enteric organisms. In 1965 and 1966, peritonitis was eliminated by a regimen consisting of prophylactic oral administration of neomycin and employment of a thin stylet-catheter which was introduced percutaneously, used for only two to three days, and reinserted thereafter as necessary. Protective isolation of the patient and prophylactic use of tetracycline in the dialysis fluid appeared to be unnecessary and were abandoned.
Amerikanische Streiflichter von Carl Beck.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICAL NEWS
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.
Authors: Mansoor Raza Mirza, Elisabeth Avall-Lundqvist, Michael J. Birrer, Rene dePont Christensen, Gitte-Bettina Nyvang, Susanne Malander, Maarit Anttila, Theresa Louise Werner, Bente Lund, Gabriel Lindahl, Sakari Hietanen, Ulla Peen, Maria Dimoula, Henrik Roed, Anja Ør Knudsen, Louisa Boufercha, Synnove Staff, Anders Krog Vistisen, Line Bjørge, Johanna Unelma Maenpaa
Journal: Journal of Clinical Oncology (2019)

5505 Background: Standard treatment of platinum-sensitive recurrent ovarian cancer (PSROC) is platinum based combination chemotherapy ± bevacizumab. However, this treatment modality is hardly curative, and is associated with significant toxicity. Both bevacizumab (BEV) and PARP inhibitors (PARPi) have demonstrated efficacy in PSROC. There is preclinical evidence of enhanced activity of the combination. This is the proof-of-concept randomized trial of PARPi-BEV combination against PARPi monotherapy as treatment in PSROC, regardless of number of previous lines of therapies. Methods: In this randomized, open-label, phase 2 study, women with measurable/evaluable, high-grade serous or endometrioid PSROC were randomized to niraparib 300mg once daily or the combination of niraparib 300mg once daily and BEV 15mg/kg IV every 3 weeks until disease progression (1:1 randomization). The primary endpoint was progression-free survival (PFS). Stratification was according to homologous recombination-deficiency(HRD) status (MyChoice HRD) and chemotherapy-free-interval (CFI)(6-12months (mo) vs. &gt;12mo). First-line maintenance bevacizumab was permitted. Results: Of 97 enrolled patients, 48 were randomized to niraparib monotherapy and 49 to the chemotherapy-free combination. The combined treatment significantly improved PFS compared to niraparib alone: median 11.9 vs. 5.5 mo; hazard ratio (HR) adjusted for stratification factors 0.35; 95% confidence interval (CI),[0.21 to 0.57]; P&lt;0.001. Pre-planned exploratory subgroup analyses: patients with HRD-positive tumors (n=54) HR 0.36 (CI, 0.18-0.69); HRD-negative disease (n=43) HR, 0.47 (CI, 0.24-0.95); g BRCAmut patients (n=34) HR 0.53 (CI, 0.23-1.21); non-g BRCAmut patients (n=63) HR 0.33; CI, 0.18-0.61); CFI of 6 to 12 mo (n=38) HR, 0.29 (CI, 0.14 to 0.62); CFI of ≥12 mo (n=59) HR, 0.42; (CI, 0.22 to 0.80). There was no difference in treatment-emergent grade 3-4 adverse events except for the rate of hypertension (26.5% vs. 0%) and neutropenia (12.2% vs. 2.1%). Patient-reported outcomes measured using EORTC QLQ-C30 and OV28 were similar for both treatment arms. Conclusions: Both niraparib alone and the combination had meaningful activity in PSROC. Compared to niraparib alone, the chemotherapy-free regimen of niraparib and BEV significantly improved PFS in women with PSROC,regardless of HRD status and duration of CFI. Clinical trial information: NCT02354131.
Relationship between Allergic Contact Dermatitis and Electrophilicity
Authors: Herbert S. Rosenkranz, Gilles Klopman, Ying Ping Zhang, Cynthia Graham, Meryl H. Karol
Journal: Environmental Health Perspectives (1999)

To evaluate the role of electrophilicity in the induction of allergic contact dermatitis (ACD) in humans, we compared the structure-activity relationship (SAR) model of ACD with those of electrophilic and nonelectrophilic subsets of chemicals in the ACD database. For these analyses, electrophilicity was defined as the potential of a chemical to induce mutations in Salmonella. It was found that electrophilicity accounted for approximately 30-40% of ACD-inducing ability, and the remainder was associated with nonelectrophilic structures. The identification of these moieties opens the possibility for studying their role in ACD.
In This Issue
Journal: Arthritis & Rheumatology (2019)

Association of Myocardial Inflammation With Disease Activity in Rheumatoid ArthritisIn this issue, Amigues et al (p.496) report the results of the first study to evaluate and quantify subclinical myocardial inflammation in patients with rheumatoid arthritis (RA) using 18-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET-CT).The authors found that myocardial inflammation is common in patients with RA.The study included 119 patients, with FDG uptake visually observed in 39% of patients and an abnormal, quantitatively assessed myocardial FDG uptake shown in 18% of patients.Using the Clinical Disease Activity Index (CDAI) score to distinguish between patients with moderate-to-high disease activity (score of ≥10) and lower disease activity or remission (score of <10), the researchers found that the mean of the mean standardized uptake value (SUVmean) was 31% higher in patients with moderate-tohigh disease activity than it was in patients with low disease activity or remission.The
Ensuring Insurance
Authors: Mike Mitka
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal